ReviewInternational journal of molecular sciences2021
Macrophages/Microglia in the Glioblastoma Tumor Microenvironment.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Peptide-mediated inhibition of aberrant chaperone-mediated autophagy in pericytes prevents glioblastoma progression through MAPT/tau secretion.Autophagy · 2026Article
- Review
- Dual-Function Lipid-Based Nanovector Strategy for Glioblastoma Immunotherapy: STING Activation and M1 Microglia Polarization.Drug development research · 2026Review
- NG2-targeting macrophages inhibit 3D invasion of patient-derived glioblastoma spheroids.bioRxiv : the preprint server for biology · 2026Article
- TREM1 unleashes immunosuppression in glioma: targeting macrophage polarization as a new therapeutic vulnerability.Frontiers in immunology · 2026Article
- A transcriptome-defined TAM-rich phenotype identifies a macrophage-enriched, hypoxia-linked immune contexture in glioblastoma: multi-cohort transcriptomic validation and local histopathological correlation.Frontiers in immunology · 2026Article
- NOD1/RIP2 Pathway Promotes Glioma Progression Through Microglial M2 Polarization.CNS neuroscience & therapeutics · 2025Article
- Role of Colony Stimulating Factor 1 (CSF-1) and Its Receptor CSF1R: Macrophage Repolarization for Glioblastoma Treatment.ACS pharmacology & translational science · 2025Review
- IDO2-AhR axis as central regulator of the kynurenine pathway in glioblastoma.Journal of neuro-oncology · 2025Article
- Glycosylation Gene Signatures as Prognostic Biomarkers in Glioblastoma.Annals of clinical and translational neurology · 2025Article
- Bioactive Polysaccharides fromMolecules (Basel, Switzerland) · 2025Review
- CAR T cell therapy for central nervous system solid tumors: current progress and future directions.Frontiers in immunology · 2025Review
- ZnPPIX-Loaded Nanoemulsions Reprogram Immunosuppressive Macrophages in Vitro: A Potential Strategy for Glioblastoma Microenvironment Modulation.International journal of nanomedicine · 2025Article
- The role of immune- and lipid metabolism-related genes in macrophage polarization and prognosis of glioblastoma.Frontiers in oncology · 2025Article
- Unveiling the novel value of TREM1 in the proneural-mesenchymal transition of glioma via tumor-associated macrophages.Frontiers in immunology · 2025Article
- Expression of Lumican and Osteopontin in Perivascular Areas of the Glioblastoma Peritumoral Niche and Its Value for Prognosis.International journal of molecular sciences · 2024Article
- Review
- The role of NLRP3 and NLRP12 inflammasomes in glioblastoma.Genes and immunity · 2024Review
- CAR T-cell therapy: a potential treatment strategy for pediatric midline gliomas.Acta neurologica Belgica · 2024Review
- Prognostic relevance of high expression of kynurenine pathway markers in glioblastoma.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The complex interaction between glioblastoma and its microenvironment has been recognized for decades. Among various immune profiles, the major population is tumor-associated macrophage, with microglia as its localized homolog. The present definition of such myeloid cells is based on a series of cell markers. These good sentinel cells experience significant changes, facilitating glioblastoma development and protecting it from therapeutic treatments. Huge, complicated mechanisms are involved during the overall processes. A lot of effort has been dedicated to crack the mysterious codes in macrophage/microglia recruiting, activating, reprogramming, and functioning. We have made our path. With more and more key factors identified, a lot of new therapeutic methods could be explored to break the ominous loop, to enhance tumor sensitivity to treatments, and to improve the prognosis of glioblastoma patients. However, it might be a synergistic system rather than a series of clear, stepwise events. There are still significant challenges before the light of truth can shine onto the field. Here, we summarize recent advances in this field, reviewing the path we have been on and where we are now.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.